Trials / Completed
CompletedNCT00806520
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 16 (actual)
- Sponsor
- HealthPartners Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and during treatment.
Conditions
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2008-12-10
- Last updated
- 2015-12-02
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00806520. Inclusion in this directory is not an endorsement.